Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis
1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in ...
Tag: systemic JIA
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...